Bank of America Securities Raises PT on Metsera (MTSR), Keeps a Buy

Metsera, Inc. (NASDAQ:MTSR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 28, Bank of America Securities analyst Tim Anderson raised the firm’s price target on Metsera, Inc. (NASDAQ:MTSR) from $45 to $50, while maintaining a Buy rating on the stock.

The improved bullish sentiment for the stock comes after the company reported financial and business updates for its fiscal second quarter of 2025. The company reported notable progress in its obesity and metabolic disease drug pipeline for mid-2025. Its lead drug, MET-097i, which is a once-monthly GLP-1 receptor agonist, showed strong potential for weight loss and good tolerability in Phase 2b trials. Moreover, data from VESPER-1 and interim VESPER-3 studies are expected in September 2025.

Moreover, another drug, MET-233i, which is a once-monthly amylin analog, delivered impressive Phase 1 results, with an 8.4% weight loss over five weeks and a 19-day half-life. Management is expecting full 12-week monotherapy data by late 2025. Similarly, the company is also advancing oral peptide programs, with data from MET-097o and MET-224o expected in late 2025 as well.

Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biotechnology company developing innovative injectable and oral hormone analog peptides.

While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.